Companies
/Healthcare
Deciphera Pharmaceuticals Inc
$25.59
▲ $0.00 (+0.00%) today
Markets open · 11:15am ET
DCPH at a Glance
Valuation
- Market cap
- $2.2B
Profitability
- Revenue (TTM)
- $174.9M
- Profit margin
- -108.9%
- EPS (TTM)
- $-2.21
Price
- Street target
- $27.52
Headquartered in Waltham, MA Fiscal year ends December NASDAQ: DCPH deciphera.com
About DCPH
Deciphera Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative drugs to improve the lives of cancer patients. With a keen eye on overcoming drug resistance, its flagship product, QINLOCK, is designed for treating gastrointestinal stromal tumors. The company is also working on vimseltinib for tenosynovial giant cell tumor and DCC-3116 for RAS/RAF mutant cancers. Founded in 2003 and based in Waltham, Massachusetts, Deciphera is committed to advancing cancer treatment options worldwide.
Frequently Asked Questions
What does DCPH do?
Deciphera Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative drugs to improve the lives of cancer patients. With a keen eye on overcoming drug resistance, its flagship product, QINLOCK, is designed for treating gastrointestinal stromal tumors.
What is the DCPH stock price target?
The Wall Street consensus 12-month price target for DCPH is $27.52.